TG Therapeutics upgrades rating to Buy amid strong 2026/2027 catalysts and higher Briumvi revenue forecast

TG Therapeutics is expected to have significant catalysts in late 2026 and early 2027, including Phase 1 data for a progressive MS treatment and Phase 3 data for Briumvi SC. The company raised its U.S. net revenue forecast for Briumvi from $885-$900 million to $890-$905 million. These developments have led ALLKA Research to upgrade TG Therapeutics' stock rating from Hold to Buy, signaling confidence in the company's growth prospects.